Stay updated on Dauno/Cytarabine ± Uproleselan in AML Clinical Trial
Sign up to get notified when there's something new on the Dauno/Cytarabine ± Uproleselan in AML Clinical Trial page.

Latest updates to the Dauno/Cytarabine ± Uproleselan in AML Clinical Trial page
- CheckyesterdayChange DetectedA site-wide NIH notice says agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference0.1%

- Check8 days agoChange DetectedThe site footer now identifies the ClinicalTrials.gov release as v3.7.2 instead of v3.7.1.SummaryDifference0.0%

- Check15 days agoChange DetectedThe footer revision label was updated from v3.7.0 to v3.7.1, with no change to the study record.SummaryDifference0.0%

- Check35 days agoChange DetectedRecord history now includes a new revision entry v3.7.0. The prior revision v3.6.6 has been removed from the visible history.SummaryDifference0.0%

- Check57 days agoChange DetectedA new revision entry, v3.6.6, was added to the record history and the older revision v3.6.5 was removed, indicating an update to the study record.SummaryDifference0.0%

- Check78 days agoChange DetectedRevision tag updated from v3.6.4 to v3.6.5, indicating a minor internal update to the page. This does not affect the study data or public content.SummaryDifference0.0%

Stay in the know with updates to Dauno/Cytarabine ± Uproleselan in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dauno/Cytarabine ± Uproleselan in AML Clinical Trial page.